Accueil › Cancer du poumon non à petites cellules › Pennsylvanie
Essais cliniques pour Cancer du poumon non à petites cellules dans Pennsylvanie
103 études pour Cancer du poumon non à petites cellules recherchent des participants dans Pennsylvanie.
Villes dans Pennsylvanie
- Philadelphia51 études
- Pittsburgh48 études
- York15 études
- Allentown14 études
- Harrisburg12 études
- Reading9 études
- Lancaster7 études
- Scranton6 études
- Chambersburg6 études
- Erie5 études
- New Castle4 études
- Hazleton4 études
- Williamsport3 études
Texte officiel de l'étude (anglais)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Lehigh Valley Hospital-Cedar Crest, Allentown
- UPMC Altoona, Altoona
- UPMC-Heritage Valley Health System Beaver, Beaver
- et 53 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- St. Lukes Hospital and Health Network ( Site 0186), Bethlehem
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT06623422A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- UPMC-Heritage Valley Health System Beaver, Beaver
- Carlisle Regional Cancer Center, Carlisle
- UPMC Hillman Cancer Center Erie, Erie
- et 17 autres
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT07293247The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
- WellSpan York Cancer Center, York
Recrutement en coursPhase 1/2
Âges de 12 ans et plus · Tous sexes · Mis à jour le 2 oct. 2026 · NCT04585750Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #104, Hershey
- Exelixis Clinical Site #98, Philadelphia
- Exelixis Clinical Site #32, Pittsburgh
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT05176483A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
- AHN Cancer Institute - Allegheny General ( Site 9501), Pittsburgh
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06780085A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Perelman Center for Advanced Medicine ( Site 3205), Philadelphia
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT07513376A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- et 14 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 1 oct. 2026 · NCT06498635A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Lancaster General Hospital, Lancaster
- Local Institution - 0028, Pittsburgh
- WellSpan Oncology Research, York
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 30 sept. 2026 · NCT07361510Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Alliance Cancer Specialists, Sellersville
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 30 sept. 2026 · NCT06765109A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Pittsburgh
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT05877599Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Spoknwrd Clinical Trials /ID# 273776, Easton
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Penn State Milton S. Hershey Medical Center, Hershey
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 29 sept. 2026 · NCT06881784A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Alliance Cancer Specialists, PC, Bensalem
- Consultants in Medical Oncology and Hematology, P.C., Broomall
- Alliance Cancer Specialists, PC, Doylestown
- et 5 autres
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 28 sept. 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Penn State Milton S. Hershey Medical Center-Penn State Cancer Institute ( Site 0059), Hershey
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06312137A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Alliance Cancer Specialists - Media, Media
- Guthrie Medical Group, Sayre
Recrutement en coursPhase 3
Âges de 18 à 100 · Tous sexes · Mis à jour le 25 sept. 2026 · NCT05920356Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Philadelphia
- Research Site, Pittsburgh
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06218914A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Health Northeast, Philadelphia
- McGlinn Cancer Institute Reading Hospital, West Reading
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06667076A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- University of Pennsylvania, Philadelphia
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06667908A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Fountain Hill
- Research Site, Kittanning
- Research Site, Philadelphia
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 25 sept. 2026 · NCT06868277Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- Jefferson Hospital Northeast, Philadelphia
- AHN Allegheny General Hospital, Pittsburgh
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 24 sept. 2026 · NCT06890598Pan-tumor MRD Study
- Lancaster General Hospital (UPenn), Lancaster
- Guthrie Foundation, Sayre
- Cancer Care Associates of York (CCAY), York
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Tous sexes · Mis à jour le 24 sept. 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Bryn Mawr Hospital, Bryn Mawr
- et 5 autres
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 24 sept. 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
- Local Institution - 0504, Philadelphia
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 23 sept. 2026 · NCT06561386Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Pittsburgh
Recrutement en coursPhase 2
Âges de 18 à 95 · Tous sexes · Mis à jour le 23 sept. 2026 · NCT05061550Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Lankenau Medical Center, Paoli
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07028489Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06128551A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Guthrie Robert Packer Hospital /ID# 270316, Sayre
- Cancer Care Associates Of York /ID# 270971, York
Recrutement en coursPhase 2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06568939Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Hospital of the University of Pennsylvania, Philadelphia
- West Penn Allegheny Health, Pittsburgh
Recrutement en coursPhase 2/3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07100080An External Control Arm Study in Non-Small Cell Lung Cancer
- Main Line Health, Wynnewood
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT07174388A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0688, Easton
- WellSpan Oncology Research, York
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 22 sept. 2026 · NCT06875310A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Hershey
- Research Site, York
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 18 sept. 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Philadelphia
- Clinical Study Site, Pittsburgh
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 18 sept. 2026 · NCT06767514A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- UPMC, Pittsburgh
Recrutement en coursPhase 1
Âges de 18 ans et plus · Tous sexes · Mis à jour le 17 sept. 2026 · NCT07020117Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Veterans Affairs Pittsburgh Healthcare System - University Drive Campus, Pittsburgh
Recrutement en coursPhase 2/3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 16 sept. 2026 · NCT04613596FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Allegheny Singer, Pittsburgh
Recrutement en coursPhase 1/2
Âges de 18 ans et plus · Tous sexes · Mis à jour le 14 sept. 2026 · NCT06303505ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- University of Pennsylvania, Philadelphia
- WellSpan Medical Oncology & Hematology at York Cancer Center, York
Recrutement en coursÉtude observationnelle
Âges de 18 ans et plus · Tous sexes · Mis à jour le 14 sept. 2026 · NCT05059444A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- St. Luke's University Health Network, Bethlehem
- Allegheny Cancer Center, Pittsburgh
- Reading Hospital - McGlinn Cancer Institute, West Reading
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 8 sept. 2026 · NCT06793215A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
Recrutement en coursPhase 3
Âges de 18 ans et plus · Tous sexes · Mis à jour le 8 sept. 2026 · NCT06345729Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.